Alector, Inc. (ALEC) Operating Margin
- Operating margin · 12 months: Value -912.40%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -912.40% | Operating income / revenue. Period ending 2026-06-30. $-126.49M ÷ $13.86M × 100 ≈ -912.40% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -126.49M USD | Operating Income (Loss) |
| Revenue | 13.86M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 99.13M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-126.49M | $13.86M | (m) | $99.13M | (m) | -912.40% |
| 2026-03-31 | $-136.23M | $18.42M | (m) | $107.28M | (m) | -739.70% |
| 2025-12-31 | $-156.01M | $21.05M | (m) | $123.06M | (m) | -741.30% |
| 2025-09-30 | $-123.69M | $69.05M | (m) | $137.06M | (m) | -179.14% |
| 2025-06-30 | $-134.52M | $81.13M | (m) | $155.71M | (m) | -165.80% |
| 2025-03-31 | $-145.98M | $88.34M | (m) | $174.41M | (m) | -165.25% |
| 2024-12-31 | $-145.00M | $100.56M | (m) | $185.94M | (m) | -144.19% |
| 2024-09-30 | $-185.20M | $61.51M | (m) | $187.20M | (m) | -301.10% |
| 2024-06-30 | $-187.35M | $55.27M | (m) | $185.53M | (m) | -338.94% |
| 2024-03-31 | $-145.33M | $96.41M | (m) | $185.40M | (m) | -150.75% |
| 2023-12-31 | $-151.74M | $97.06M | (m) | $192.12M | (m) | -156.33% |
| 2023-09-30 | $-159.72M | $96.31M | (m) | $198.88M | (m) | -165.84% |
| 2023-06-30 | $-156.89M | $102.06M | (m) | $200.91M | (m) | -153.73% |
| 2023-03-31 | $-143.83M | $125.69M | (m) | $209.26M | (m) | -114.43% |
| 2022-12-31 | $-137.83M | $133.62M | (m) | $210.42M | (m) | -103.16% |
| 2022-09-30 | $-138.13M | $133.17M | (m) | $208.72M | (m) | -103.72% |
| 2022-06-30 | $35.95M | $300.73M | (m) | $203.43M | (m) | 11.95% |
| 2022-03-31 | $-28.85M | $227.45M | (m) | $196.72M | (m) | -12.68% |
| 2021-12-31 | $-37.36M | $207.09M | (m) | $189.41M | (m) | -18.04% |
| 2021-09-30 | $-34.39M | $197.94M | (m) | $181.00M | (m) | -17.37% |
| 2021-06-30 | $-214.47M | $21.43M | (m) | $181.75M | (m) | -1000.55% |
| 2021-03-31 | $-205.73M | $18.04M | (m) | $168.00M | (m) | -1140.61% |
| 2020-12-31 | $-195.17M | $21.10M | (m) | $156.87M | (m) | -925.08% |
| 2020-09-30 | $-174.76M | $22.25M | (m) | $138.25M | (m) | -785.57% |
| 2020-06-30 | $-155.16M | $19.04M | (m) | $122.95M | (m) | -814.99% |
| 2020-03-31 | $-135.72M | $22.79M | (m) | $114.53M | (m) | -595.66% |
| 2019-12-31 | $-114.40M | $21.22M | (m) | $100.53M | (m) | -539.16% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-57.29M | $27.51M | (m) | $73.03M | (m) | -208.26% |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-32.68M | $2.87M | (m) | $29.91M | (m) | -1137.85% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |